DCs function is a bridge between the innate and adaptive immune systems and acts as attractive targets for tumor immunotherapy because of their unique ability of activating primary immune responses through the presentation of antigens to naïve CD4+ and CD8+ T cells (Li et al., 2017; Evelyn et al., 2019; Nobis et al., 2019). Here, CD8A is linked to neoplasm.